Table 3.
—Association of BMI With Plasma Biomarker Measurements at Study Day 3
| Underweight (BMI < 18.5) |
Normal (18.5 ≤ BMI < 25) |
Overweight (25 ≤ BMI < 30) |
Obese (30 ≤ BMI < 40) |
Morbidly Obese (BMI ≥ 40) |
||||||||
| Variable | No. | Pg/mLc | No. | pg/mLc | No. | pg/mLc | No. | pg/mLc | No. | pg/mLc | P Valuea (Unadjusted) | P Valueb (Adjusted) |
| IL-6 | 51 | 129 (44-468) | 453 | 99 (51-264) | 338 | 105 (49-272) | 245 | 80 (41-211) | 64 | 90.5 (33-153) | .005 | .07 |
| IL-8 | 50 | 47.8 (15.6-98) | 455 | 35.6 (15.6-76) | 336 | 31 (15.6-67.5) | 246 | 19.6 (2-58.1) | 64 | 15.6 (0-54.6) | < .001 | .92 |
| TNF-α receptor 1 | 37 | 3,878 (2,650-7,660) | 351 | 3,613.1 (2,391-6,727.7) | 280 | 3,807.5 (2,308-6,714.1) | 216 | 3,139.5 (2,167.4-6,768.4) | 57 | 3,001.2 (2,024-5,823.1) | .04 | .92 |
| SP-D | 38 | 214 (103-338) | 342 | 211 (110-388) | 272 | 164.5 (85.5-300) | 214 | 137.5 (72-244) | 57 | 111 (60-243) | < .001 | < .001 |
| sICAM | 47 | 838.2 (447.5-1,399) | 442 | 766.5 (508.6-1,255.8) | 329 | 879 (523-1,360) | 242 | 812 (405.6-1,398) | 61 | 895 (474.4-1,395) | .76 | .73 |
| vWF | 37 | 287.3 (161-480.2) | 345 | 342.8 (203-521.8) | 278 | 392.2 (238.2-607.3) | 220 | 384.0 (250.1-551.8) | 55 | 407 (255.8-587.0) | .001 | .09 |
| Protein C | 47 | 54.2 (34.3-89.1) | 444 | 62.2 (40.5-97.6) | 331 | 62.8 (42.1-95.2) | 241 | 76.6 (48.7-121.6) | 61 | 75.2 (47.2-121.8) | < .001 | .20 |
| PAI-1 | 47 | 41.4 (29.3-83.8) | 442 | 46.9 (29.9-102.2) | 331 | 48.5 (30.7-103.1) | 241 | 52.7 (32.4-114.6) | 61 | 67.5 (36.8-110.7) | .04 | .10 |
a
Wilcoxon rank sum test for trend, unadjusted.
b
When adjusted analyses of day 3 biomarker measurements were performed with an analysis of covariance model, BMI did not affect the rate of change between baseline and day 3 biomarker levels. That model includes log-transformed cytokine levels and BMI as a continuous variable with adjustment for gender, APACHE III score, comorbid diabetes, ALI risk factor, tidal volume assignment, and baseline cytokine level.
c
Median (intraquartile range).